Technical Analysis for ACUR - Acura Pharmaceuticals, Inc.
|Grade||Last Price||% Change||$ Change|
ACUR closed unchanged on Wednesday, January 18, 2017, on 1.36 times normal volume. The bears made the stock sink to a new 52-week low. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: 2017-01-30
Trend Table & Recent Alerts
|See historical ACUR trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||New 52 Week Low||Bearish||0.00%|
|Jan 18||Narrow Range Bar||Range Contraction||0.00%|
|Jan 18||Hammer Candlestick||Bullish||0.00%|
|Jan 18||Doji - Bullish?||Reversal||0.00%|
|Jan 18||Lizard Bullish||Bullish Day Trade Setup||0.00%|
|Jan 17||New 52 Week Low||Bearish||0.00%|
|Jan 13||180 Bearish Setup||Bearish Swing Setup||-7.69%|
|Jan 13||Narrow Range Bar||Range Contraction||-7.69%|
|Jan 12||Narrow Range Bar||Range Contraction||-10.45%|
|Jan 11||New Downtrend||Bearish||-9.09%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. Its products include Oxecta Tablets CII, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, an over-the-counter immediate-release pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. The company has seven additional opioid products utilizing Aversion technology in various stages of development. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc., a wholly-owned subsidiary of Pfizer Inc. to develop and commercialize certain opioid analgesic products utilizing the companys proprietary Aversion technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois.
Is ACUR a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACUR news...
|52 Week High||3.52|
|52 Week Low||0.57|
|200-Day Moving Average||1.73|
|50-Day Moving Average||0.87|
|20-Day Moving Average||0.73|
|10-Day Moving Average||0.66|
|Average True Range||0.1|
|Chandelier Exit (Long, 3 ATRs)||0.68|
|Chandelier Exit (Short, 3 ATRs)||0.87|
|Upper Bollinger Band||0.88|
|Lower Bollinger Band||0.58|
|Percent B (%b)||0.07|